scholarly journals Change in Body Weight and Long-Term Risk of Stroke and Death in Healthy Men

Stroke ◽  
2020 ◽  
Vol 51 (5) ◽  
pp. 1435-1441 ◽  
Author(s):  
Erik Prestgaard ◽  
Julian Mariampillai ◽  
Kristian Engeseth ◽  
Jan Erikssen ◽  
Johan Bodegård ◽  
...  
Keyword(s):  
Weight Loss ◽  
Weight Gain ◽  
Weight Change ◽  
Early Life ◽  
Cox Regression ◽  
Weight Increase ◽  
Healthy Men ◽  
Measured Weight ◽  
Long Term Follow Up

Background and Purpose— The importance of weight change for the risk of stroke is not well known. We examined the associations between early- and mid-life weight change and risks of stroke and death during long-term follow-up of healthy men. Methods— We recruited healthy men aged between 40 and 59 years and performed a cardiovascular examination at baseline and again at 7 years. We collected data on weight change since the age of 25 (early-life weight change) and measured weight change from baseline to the visit at 7 years (mid-life weight change). For both weight change periods, participants were divided into the following categories: weight loss, weight gain 0 to 4.9 kg, weight gain 5 to 9.9 kg, and weight gain ≥10 kg. Data on stroke and death were collected up to 35 years, from study visits, hospital records, and the National Cause of Death Registry. We used Cox regression to analyze the associations between weight change during early-life and mid-life and risks of stroke and death. Results— Of the 2014 participants, 2014 (100%) had data on early-life weight change and were followed for a median of 30.1 years, while 1403 had data on mid-life weight change and were followed for a median of 24.6 years. During early-life, compared with those who had weight gain 0 to 4.9 kg, hazard ratio for stroke was 1.46 (95% CI, 1.09–1.95) among those with weight gain 5 to 9.9 kg, 1.39 (95% CI, 1.03–1.87) for those with weight gain ≥10 kg, and 1.46 (95% CI, 0.99–2.11) among those with weight loss. For all-cause death, the hazard ratios were 1.08 (95% CI, 0.92–1.23), 1.14 (95% CI, 0.98–1.33), and 1.29 (95% CI, 1.06–1.56), respectively. During mid-life, there were no significant differences in risk of stroke or death between the groups. Conclusions— Weight increase during early-life, but not mid-life, seems to be associated with increased long-term risk of stroke in healthy men. If these findings can be confirmed, efforts to prevent weight increase should target the younger population.

The weight change impact on metabolic syndrome: a 17-year follow-up study

Open Medicine ◽  
2011 ◽  
Vol 6 (6) ◽  
pp. 788-794 ◽  
Author(s):  
Magdalena Kwaśniewska ◽  
Dorota Kaleta ◽  
Anna Jegier ◽  
Tomasz Kostka ◽  
Elżbieta Dziankowska-Zaborszczyk ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Weight Loss ◽  
Weight Gain ◽  
Weight Change ◽  
Metabolic Risk ◽  
Adjusted Relative Risk ◽  
Prospective Longitudinal ◽  
The Impact

AbstractIntroduction: Data on long-term patterns of weight change in relation to the development of metabolic syndrome (MetS) are scarce. The aim of the study was to evaluate the impact of weight change on the risk of MetS in men. Material and Methods: Prospective longitudinal observation (17.9 ± 8.1 years) of apparently healthy 324 men aged 18–64 years. Metabolic risk was assessed in weight gain (⩾ 2.5 kg), stable weight (> −2.5 kg and < 2.5 kg) and weight loss (⩽ −2.5 kg) groups. Adjusted relative risk (RR) of MetS was analyzed using multivariate logistic regression. Results: The prevalence of MetS over follow-up was 22.5%. There was a strong relationship between weight gain and worsening of MetS components among baseline overweight men. Long-term increase in weight was most strongly related with the risk of abdominal obesity (RR=7.26; 95% CI 2.98–18.98), regardless of baseline body mass index (BMI). Weight loss was protective against most metabolic disorders. Leisure-time physical activity (LTPA) with energy expenditure > 2000 metabolic equivalent/min/week was associated with a significantly lower risk of MetS. Conclusions: Reducing weight among overweight and maintaining stable weight among normal-weight men lower the risk of MetS. High LTPA level may additionally decrease the metabolic risk regardless of BMI.

scholarly journals Treatment-Related Weight Change and Overall Survival in United States Veterans with Follicular Lymphoma

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 2088-2088
Author(s):  
Daphne Y Xiao ◽  
Katiuscia O'Brian ◽  
Suhong Luo ◽  
Kenneth R Carson
Keyword(s):  
Overall Survival ◽  
Weight Loss ◽  
Weight Gain ◽  
Weight Change ◽  
Treatment Initiation ◽  
Disease Specific Survival ◽  
Baseline Weight ◽  
Cox Analysis ◽  
Disease Specific

Abstract Introduction Weight loss during chemotherapy has been associated with decreased overall survival (OS) in various solid tumors. While weight loss >10% in the 6 months leading up to diagnosis is a known adverse prognostic factor for non-Hodgkin's lymphoma (one of the B symptoms), the association between weight loss during chemotherapy and survival in follicular lymphoma (FL) patients is not well understood. Few studies have looked at long-term weight change patterns following chemotherapy treatment in this patient population. We investigated short and long-term weight change trends, predictors, and association with OS and disease-specific survival (DSS) in a cohort of FL patients. Methods FL patients diagnosed and treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) +/- rituximab, CVP (cyclophosphamide, vincristine, and prednisone) +/- rituximab, or rituximab monotherapy regimens between 1998 and 2010 were identified in the Veterans Health Administration database. Data on weight 1 year prior to treatment, at time of first treatment (baseline), and up to 5 years after treatment initiation was obtained. Additional data on height, age, stage, race, comorbidities, date of diagnosis, LDH, and B-symptoms was obtained. Body Mass Index (BMI) at diagnosis was categorized according to World Health Organization criteria. Weight change during treatment is calculated as difference between baseline weight and 3 months after start of treatment. Long-term weight change is calculated as difference between baseline weight and 24 months after start of treatment. Logistic regression identified factors associated with long-term weight gain. Landmark Cox analysis evaluated prognostic significance of weight loss during treatment among patients who survived at least 6 months after treatment initiation. Results 1022 patients met inclusion criteria out of 2235. Mean and median age at diagnosis was 63.6 and 63.0 years respectively, 95.9% were men, and 72.7% had Stage III/IV disease. The mean Charlson co-morbidity score was 2.3. B symptoms were present in 37.9% and LDH was elevated in 26.8%. Mean and median weight change during treatment was -1.4kg (-1.5%) and -0.4kg (-0.6%), with a majority of patients losing weight (56%) and 23% of patients losing >5% of their baseline weight. In contrast, mean and median weight change at 24 months after treatment initiation was +1.2kg (+1.6%) and +1.3kg (+1.6%), with a majority of patients (57%) gaining weight and 14% of patients gaining >10% of their baseline weight after treatment completion. Logistic regression analysis identified factors associated with increased risk of weight gain >10% at 24 months after treatment initiation. These included: weight loss >5% in the year prior to treatment (Odds Ratio (OR) 6.82, 95% Confidence Interval (CI) 3.09-15.05), weight gain between 0-5% during treatment (OR 2.53, 95% CI 1.21-5.27), and weight gain >5% during treatment (OR 9.43, 95% CI 3.85-23.14). Kaplan-Meier survival analysis showed that weight loss >5% during treatment was associated with decreased OS (p<0.0001) and disease specific survival (DSS) (p=0.0027) compared to weight loss <5% or weight gain. A landmark Cox analysis controlling for age, disease stage, comorbidities, elevated LDH, B symptoms, BMI at diagnosis, and treatment type showed that weight loss >5% during treatment was independently associated with worse OS (Hazard Ratio (HR) 1.71, 95% CI 1.32-2.22) and DSS (HR 1.61, 95% CI 1.11-2.34). Conclusions In patients with FL, weight loss >5% during treatment is independently predictive of worse overall survival and disease-specific survival. Weight loss could be considered in conjunction with other dynamic variables (such as PET positivity and nodal size) to assess prognosis at the end of therapy. 14% of patients experience long-term weight gain >10% of baseline. Patients who gained 5% or more during treatment are at highest risk (OR=9.4) for long-term weight gain-this subset of patients could be targeted for weight loss interventions to prevent future obesity-related comorbidities. Disclosures No relevant conflicts of interest to declare.

scholarly journals Association of Weight Loss from Early to Middle Adulthood and Incident Hypertension Risk Later in Life

Nutrients ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 2622
Author(s):  
Yunping Zhou ◽  
Tao Wang ◽  
Xin Yin ◽  
Yun Sun ◽  
Wei Jie Seow
Keyword(s):  
Weight Loss ◽  
Weight Gain ◽  
Weight Change ◽  
Lower Risk ◽  
Cox Regression ◽  
Early Adulthood ◽  
Later Life ◽  
Normal Weight ◽  
Middle Adulthood ◽  
Incident Hypertension

Background: The effect of obesity in early adulthood and weight loss on incident hypertension in older age has not been well characterized. This study aimed to examine the association of weight loss from young adulthood to midlife with risk of incident hypertension later in life. Methods: We performed a retrospective cohort study using data from the National Health and Nutrition Examination Survey (NHANES). Five weight change groups were categorized: stable normal, weight loss, weight gain, maximum overweight and stable obese. The hazard ratios (HRs) and 95% confidence intervals (CIs) of the association between weight change and risk of hypertension in later life were estimated using Cox regression models. Results: Compared with participants who maintained normal weight, the stable obese, weight gain, maximum overweight and weight loss groups exhibited significantly higher risks of incident hypertension, with HR of 3.28 (95% CI = 2.71 to 3.96), 2.93 (95% CI = 2.62 to 3.28), 1.76 (95% CI = 1.55 to 2.00) and 1.97 (95% CI = 1.17 to 3.31), respectively. We also observed a lower risk among those in the weight loss group (HR = 0.60, 95% CI = 0.35 to 1.02) compared with those who were stable obese. Conclusions: Weight loss from early to middle adulthood was associated with lower risk of incident hypertension as compared to those who stayed obese and higher risk of incident hypertension as compared to those who maintained normal weight. Thus, maintaining normal weight throughout adulthood may be important for the primary prevention of hypertension.

scholarly journals SAT-436 Long-Term Analysis of Weight Change Following Thyroidectomy

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Reece Moore ◽  
Parker McDuffie ◽  
Keri Broadley ◽  
Denise Carneiro-Pla ◽  
Mahsa Javid
Keyword(s):  
Weight Gain ◽  
Weight Change ◽  
Weight Increase ◽  
Common Source ◽  
Weight Changes ◽  
Thyroid Cancer Patient ◽  
Significant Difference ◽  
Post Operation

Abstract Introduction: Weight gain is a common source of apprehension for patients undergoing thyroidectomy. However, contradictory reports exist regarding the presence and degree of weight gain following thyroid surgery and all known studies have short term follow-up This study evaluated weight changes following total thyroidectomy (TT) and lobectomy (L) over an extended time period. Methods: Retrospective analysis was performed of weight changes following surgery for patients who underwent TT or L (n=387) as compared with those undergoing parathyroidectomy for primary hyperparathyroidism (n=201) in a tertiary referral hospital between 2007-2012. Clinical, demographic and pre- and postoperative weight data was collected with a median follow-up of 55.6 months. Results: Postoperative weight change was observed at 1, 6, 12, and 36-months in patients who underwent TT (μ=+0.21kg, μ=+1.33kg, μ=+0.59kg, μ=+0.60kg; p&lt;0.05) and at 6-months for patients who underwent L (μ=+0.93kg, p&lt;0.05) compared with those who underwent parathyroidectomy. Patients having TT and L showed a general trend of weight gain compared to the control group up to 108-months post-operation; however, this weight gain was non-significant (p&lt;0.05). Significant postoperative weight gain was observed in patients who had TT (1-month μ=+0.40kg, 6-months μ=+2.14kg, and 12-months μ=+1.40kg) and L (6-months μ=+1.04kg) for benign conditions compared with the parathyroidectomy group. Patients who had TT gained 0.40kg more than L patients at 12-months post-op (p&lt;0.05), but no significant difference existed at other time points up to 108-months. Tukey HSD post-hoc analysis showed weight gain in benign, thyroiditis, and thyroid cancer patient groups was not significantly different from 6-months to 108-months post-operation. Furthermore, neither race nor sex was correlated with weight gain. Relative risks with 95% CI for weight gain following TT and L compared to control are: 1-month TT=1.74, 0.96-3.14, L=1.59, 0.58-2.58; 6-month TT=1.27, 0.85-1.89, L=1.42, 0.85-2.11; 12-month TT=1.44, 0.92-2.28, L=1.34, 0.86-2.36; 24-month TT=1.17, 0.82-1.67, L=1.22, 0.69-1.60. In the group of patients who gained greater than 2kg, those who underwent TT had significant weight increase compared to the parathyroidectomy group at 6-months postoperatively (Mann-Whitney U, p=0.011). In the subgroup of patients with weight gain greater than 2kg, those who had L did not have significant weight increase at any time point. Conclusion: Weight change following TT when compared with parathyroidectomy is significant shortly after surgery. However, these changes are not significant at long-term follow-up.

Treatment-Related Weight Change In United States Veterans With Non-Hodgkin Lymphoma

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 2972-2972
Author(s):  
Arun Ganti ◽  
Katiuscia O'Brian ◽  
Weijian Liu ◽  
Suhong Luo ◽  
Kenneth R. Carson
Keyword(s):  
Weight Loss ◽  
Weight Gain ◽  
Hodgkin Lymphoma ◽  
Weight Change ◽  
Treatment Initiation ◽  
Disease Stage ◽  
B Spline ◽  
Non Hodgkin Lymphoma ◽  
Baseline Weight

Abstract Introduction Prior studies have demonstrated weight gain among recipients of chemotherapy for various solid tumors, though there is little evidence describing weight changes during and after treatment in patients with non-Hodgkin lymphoma (NHL). Weight gain during and after treatment can contribute to an increased risk of chronic conditions including: diabetes, coronary disease, and hypertension. This is important for long-term health in patients with diseases that are potentially curable or associated with long-disease free intervals, such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). We investigated the magnitude of weight change during and after treatment in a cohort of DLBCL and FL patients. Methods DLBCL and FL patients diagnosed between 1998 and 2008 and treated with combination chemotherapy +/- rituximab, were identified in the Veterans Health Administration database. Data on weight at time of first treatment (baseline) and at all recorded weight measurements up to 5 years after treatment initiation was obtained. Additional data included: height, age, race, co-morbidities, date of diagnosis, disease stage, LDH at diagnosis, B-symptoms, and treatment details (drugs, dates, and dosages). Only patients treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) +/- rituximab or CVP (cyclophosphamide, vincristine, and prednisone) +/- rituximab were included in the study cohort. Patients were categorized as gaining or losing 0-2.5%, 2.5-5%, 5-7.5%, 7.5-10%, or >10% of baseline weight. Weight change during treatment was calculated utilizing baseline and weight measurement at or near 3 months following treatment initiation. B-spline modeling was applied to further evaluate trends in weight change over time within the cohort. Results 2,159 patients met inclusion criteria. Mean age at diagnosis was 63.1 years, 96.6% of patients were men, and 59.5% of patients had stage III/IV disease. Mean Charlson co-morbidity score was 2.2. B-symptoms were noted at diagnosis in 48.4% of patients and LDH was elevated in 47.2% of patients. Mean and median weight change at 3 months after treatment initiation were -1.9 kg and -1.1 kg respectively, or -2.1% and -1.3% of baseline weight. Figure 1 illustrates the distribution of weight change during treatment within the cohort. In B-spline analysis, weight loss was maximal at 4.14 months after first treatment, with subsequent weight gain until reaching a plateau at 22 months (Figure 2). Among patients with 24 months or more of follow-up data, 45.7% had gained weight at 3 months and 60.5% had gained weight at 24 months. Only 4.3% of patients had gained >10% of baseline weight at 3 months, while 23.0% had gained >10% at 24 months. Similarly, 15.4% of patients had gained >5% of baseline weight at 3 months, while 38.5% had gained >5% at 24 months. Of the patients that gained weight at 3 months, 9.3% had gained >10% of baseline weight, while of the patients that gained weight at 24 months, 38.0% had gained >10%. Patients who gained weight in the first 3 months after treatment initiation were more likely to gain >10% baseline weight at 24 months compared to those who lost weight in the first 3 months. Discussion These results suggest that in contrast to other malignancies, most patients with NHL who are treated with multi-agent chemotherapy actually experience weight loss rather than weight gain over the course of treatment. Despite this initial trend, a majority of these patients undergo significant weight gain after the conclusion of therapy and in subsequent months. This poses a long-term health risk, particularly to patients who achieve a complete remission and long-term disease control. The timing of greatest weight gain in the 6-18 months after treatment initiation suggests an opportune time for initiation of a diet or exercise intervention to reduce weight gain shortly after the end of treatment. Disclosures: No relevant conflicts of interest to declare.

Interferon-free cure of chronic Hepatitis C is associated with weight gain during long-term follow-up

2017 ◽  
Vol 55 (09) ◽  
pp. 848-856 ◽  
Author(s):  
Bernhard Schlevogt ◽  
Katja Deterding ◽  
Kerstin Port ◽  
Christoph Siederdissen ◽  
Lisa Sollik ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Weight Gain ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Weight Change ◽  
Antiviral Treatment ◽  
Long Term Effects ◽  
Long Term Follow Up

Abstract Background and aim The advent of direct-acting antivirals has revolutionized treatment of chronic hepatitis C with very high cure rates and excellent tolerability compared to interferon-based hepatitis C virus (HCV) treatment. However, long-term effects of interferon-free cure of HCV infection on the metabolic condition of patients have not been investigated so far. Methods We investigated weight development during and after antiviral treatment of hepatitis C. In a prospective single-center cohort study, interferon-free antiviral treatment was initiated in 284 patients. Each patient’s weight was monitored 1 year before the start of treatment, at baseline (BL), end of treatment (EOT), follow-up week 24 (FU24), and follow-up week 48 (FU48). Results Weight gain after HCV cure was observed in 20 %, 33 %, and 44 % of patients at EOT, FU24, and FU48, respectively. The mean overall weight change at FU48 compared to baseline was 1.45 kg (95 % CI 0.44; 2.46, p = 0.02, compared to the pretreatment period). Multivariate regression revealed age as the only factor predicting weight change at FU48 (B − 0.107, 95 % CI, − 0.202 to − 0.011, p = 0.03), while gender, cirrhosis, diabetes mellitus, ribavirin, and body mass index had no influence. In the subgroup of patients younger than 60 years, mean weight gain at FU48 compared to baseline was 2.8 kg (95 % CI, 1.23 – 4.4). In contrast, patients 60 years and older had a mean weight change of − 0.04 kg (95 % CI, − 1.12 to 1.03, p = 0.005). Conclusions Cure of HCV by interferon-free antiviral treatment was associated with weight gain in up to 44 % of patients during long-term follow-up. Weight gain occurred predominantly in patients younger than 60 years. The precise mechanism of weight gain remains to be elucidated.

scholarly journals T199. 7% WEIGHT CHANGE ASSOCIATED WITH ANTIPSYCHOTICS: A META-ANALYSIS

2020 ◽  
Vol 46 (Supplement_1) ◽  
pp. S307-S308
Author(s):  
Joost Crins ◽  
Bea Campforts ◽  
Marjan Drukker ◽  
Maarten Bak
Keyword(s):  
Weight Loss ◽  
Weight Gain ◽  
Weight Change ◽  
Antipsychotic Drugs ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Statistical Significance ◽  
Insufficient Data ◽  
Data Set

Abstract Background In recent years, antipsychotic-induced weight gain (AIWG) has gained more attention in research. Although interventions to prevent weight gain are currently being investigated, AIWG remains a major problem for both patients and clinicians and often results in poor treatment adherence, a decrease in quality of life. Furthermore, schizophrenia is associated with higher mortality rates and a decreased life expectancy. Recently, some new antipsychotic drugs have been introduced that are hypothesised to entail no or low incidences of clinically relevant weight gain (CRWG), and high incidences of clinically relevant weight loss (CRWL). Here ‘clinically relevant’ is defined as &gt;7% weight change. In this meta-analysis, we aim to give a complete overview of both CRWG and CRWL, including these newer antipsychotics. Methods We searched Pubmed, Embase and Psychinfo for randomized clinical trials of antipsychotics that reported 7% weight change in study populations aged 18 years or older. We performed meta-analyses stratified by study duration (&lt;6 weeks, 6–16 weeks, 16–38 weeks and &gt;38 weeks) with a random effects model. Results The search yielded in total 941 articles. Ninety-two articles could be included in the meta-analysis, resulting in 341 records in the data set. All data were related to AP switch patients, no data on AP-naïve patients were found. During SIRS final results will be presented. Preliminary results showed that haloperidol, paliperidone and quetiapine had relatively low CRWG (16.6%, 18.7% and 18.4%, respectively), aripiprazole and risperidone had relatively high percentages of CRWG (25.4% and 24.0%, respectively). Olanzapine (29.5%) and lurasidone (7.4%) resulted in respectively the highest and lowest CRWG at &gt;38 weeks of treatment. In the placebo group, CRWG was 3.8%. Incidences of CRWG continued to rise even after 38 weeks of treatment in most treatment groups. CRWL occurred with all antipsychotic drugs; at 6–16 weeks aripiprazole (7.9%) and ziprasidone (7.1%) had CRWL similar to placebo (8.7%). We found insufficient data on CRWL in the long term (&gt;38 weeks) to draw any conclusions. Discussion All antipsychotics can result in both weight gain and weight loss. Previous research showed that patients more often gain weight than lose weight (Bak, 2014) and this is replicated in the present meta-analysis. Proportions CRWG and CRWL seem different between the antipsychotics. Future network meta-analysis are needed to test statistical significance of those differences. It appears, however, that CRWG is higher in patients receiving antipsychotics drugs compared to placebo. No conclusions can be drawn on CRWL due to insufficient data. It is clear that after &gt;38 weeks of treatment, no ‘plateau’ phase is reached as CRWG continued to increase. More future research is needed on long-term weight effects on both CRWG and CRWL to give a clear overview on the ‘real’ effects on weight, as the majority of studies had a duration of less than 26 weeks. Furthermore, more research is needed on the long-term dose-response relationship in CRWG, as this could prove to be a method for managing weight in some patients.

scholarly journals Depression-related weight change and incident diabetes in a community sample

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Eva Graham ◽  
Tristan Watson ◽  
Sonya S. Deschênes ◽  
Kristian B. Filion ◽  
Mélanie Henderson ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Weight Loss ◽  
Weight Gain ◽  
Weight Change ◽  
Short Form ◽  
Community Sample ◽  
Overweight And Obesity ◽  
Community Dwelling ◽  
Increased Risk

AbstractThis cohort study aimed to compare the incidence of type 2 diabetes in adults with depression-related weight gain, depression-related weight loss, depression with no weight change, and no depression. The study sample included 59,315 community-dwelling adults in Ontario, Canada. Depression-related weight change in the past 12 months was measured using the Composite International Diagnostic Interview—Short Form. Participants were followed for up to 20 years using administrative health data. Cox proportional hazards models compared the incidence of type 2 diabetes in adults with depression-related weight change and in adults with no depression. Adults with depression-related weight gain had an increased risk of type 2 diabetes compared to adults no depression (HR 1.70, 95% CI 1.32–2.20), adults with depression-related weight loss (HR 1.62, 95% CI 1.09–2.42), and adults with depression with no weight change (HR 1.39, 95% CI 1.03–1.86). Adults with depression with no weight change also had an increased risk of type 2 diabetes compared to those with no depression (HR 1.23, 95% CI 1.04–1.45). Associations were stronger among women and persisted after adjusting for attained overweight and obesity. Identifying symptoms of weight change in depression may aid in identifying adults at higher risk of type 2 diabetes and in developing tailored prevention strategies.

scholarly journals Long-term follow-up results of medial opening wedge high tibia osteotomy with a pre-countered non-locking steel plate

2021 ◽  
Author(s):  
Simo S. A. Miettinen ◽  
Hannu J. A. Miettinen ◽  
Jussi Jalkanen ◽  
Antti Joukainen ◽  
Heikki Kröger
Keyword(s):  
Risk Factors ◽  
Adverse Events ◽  
Mechanical Axis ◽  
Steel Plate ◽  
Cox Regression ◽  
Opening Wedge ◽  
Cumulative Survival ◽  
Long Term Follow Up

Abstract Introduction This retrospective study investigated the long-term follow-up results of medial opening wedge high tibial osteotomy (MOWHTO) with a pre-countered non-locking steel plate implant (Puddu plate = PP) used for medial knee osteoarthrosis (OA) treatment. Materials and methods Consecutive 70 MOWHTOs (66 patients) were performed between 01.01.2004 and 31.12.2008 with the mean follow-up time of 11.4 (SD 4.5; range 1.2–16.1) years. The Kaplan–Meier survival analysis was used to evaluate the cumulative survival of the implant in terms of age (< 50 years old and ≥ 50 years old) and gender. Adverse events were studied and Cox regression analysis was used to evaluate risk factors [age, gender, body mass index (BMI), preoperative mechanical axis, severity of OA, use of bone grafting or substitution and undercorrection of mechanical axis from varus to valgus] for revisions. Results The estimates for the cumulative survival with no need for TKA after MOWHTO were 86% at 5 years, 67% at 10 years and 58% at 16.1 years (SE 0.6, CI 95% 11.1–13.5). A total of 33/70 (47%) adverse events occurred and 38/70 (54%) knees required some revision surgery during the follow-up. Cox regression did not show any statistically significant risk factors for revision. Conclusions The PP has feasible MOWHTO results with a cumulative survival of 67% at 10 years with no need for conversion to TKA. Many adverse events occurred and revision rate due to any reason was high. Age or gender did not have statistically significant differences in terms of survival.

Sign in / Sign up

Export Citation Format

Share Document